CorMedix

CorMedix AAQS

The The AAQS of CorMedix (CRMD) as of Oct 17, 2026 is 6. In the previous year, The AAQS was 6.00 — a change of 0.00% (lower).

AAQS

6

YoY

0.00%

Last updated:

CorMedix has a current AAQS of 6.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock CorMedix in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The CorMedix AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
6.00 USD
Jan 1, 2019
6.00 USD
Jan 1, 2020
6.00 USD
Jan 1, 2021
6.00 USD
Jan 1, 2022
6.00 USD
Jan 1, 2023
6.00 USD
Jan 1, 2024
6.00 USD
Jan 1, 2025
6.00 USD
The CorMedix AAQS history
YEARAAQSYoY
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
6—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CorMedix Stock analysis

What does CorMedix do? CorMedix Inc is a pharmaceutical company based in Berkeley Heights, New Jersey, operating within the Health Care sector. The company has 191 employees and went public via an IPO on March 25, 2010. Its website is https://cormedix.com/. CorMedix focuses on developing therapeutic products for the prevention and treatment of diseases and conditions, particularly targeting life-threatening scenarios. The company's primary product, DefenCath, is an antibacterial and antifungal solution designed to prevent bloodstream infections associated with central venous catheters in patients requiring chronic hemodialysis. DefenCath combines taurolidine at 13.5 mg/mL with heparin at 1000 USP Units/mL, intended for use in clinical settings such as hemodialysis, total parenteral nutrition, and oncology to reduce catheter-related infections and thrombosis. The company has also engaged in pre-clinical research collaborations involving taurolidine. CorMedix operates with a focus on addressing critical healthcare needs through innovative therapeutic solutions, though specific details about other products or ongoing research beyond the mentioned collaboration are not provided in the available information. CorMedix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CorMedix stock

The AAQS of CorMedix is 6 in 2025.

On Eulerpool you can find the complete historical development of The AAQS CorMedix since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — CorMedix

All Key Metrics — CorMedix